Pila Pharma enrolls first participant in PP-CT04 obesity trial of XEN-D0501

By Public Technologies
  • Pila Pharma launched dosing for Part 1 of PP-CT04, a 12-week obesity trial of oral candidate XEN-D0501.
  • No clinical results have been presented; Part 2 is slated to start once Part 1 clears an internal safety review.
  • The study aims to assess safety and tolerability, with additional readouts on drug exposure and efficacy.
  • Part 1 uses an eight-participant pilot cohort with intensified safety monitoring before broader enrollment proceeds.
  • Dosing uses individual titration to higher target exposures, seeking levels not previously tested in the program.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pila Pharma AB published the original content used to generate this news brief on September 30, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.